RxDoctor Payments Data

Alejandro Rivera Rodriguez, MD

Rheumatology · Bayamon, PRNPI 1821239393

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Amgen at 41.3% of the total. Reporting peaked in 2019 at $560 and has fallen 77.7% since, to $125 in 2025. That places this record below the midpoint for rheumatology clinicians in PR, where the typical reported total is $2,108.

$1,614in general payments, 2019–2025

Across 80 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$666
  • AbbVie$376
  • Novartis$266
  • GSK$63
  • Abiomed$56
  • AstraZeneca$42
  • plus $145 from 5 others

What the payments were for

  • Food & beverage$1,614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)41$666
AbbVie11$376
Novartis10$266
GSK4$63
Abiomed2$56
AstraZeneca2$42
Pfizer3$40
UCB, Inc.2$32
Mallinckrodt Enterprises LLC2$30
Lilly USA, LLC2$28
Hikma Pharmaceuticals USA1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614 in reported general payments places this provider in the 45th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$1,078,177
Medicare patients
466
Services billed
73,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$69,608
Actemra ActpenTocilizumab12$28,962
MethotrexateMethotrexate Sodium65$2,195
Prednisone175$1,857
Celecoxib50$1,680
Hydroxychloroquine Sulfate37$1,298
Leflunomide16$1,089
Prednisolone11$1,022
Gabapentin63$829
Duloxetine Hcl22$791
Meloxicam95$662
Ibandronate Sodium12$595
Diclofenac Sodium31$435
Allopurinol22$214
Methylprednisolone19$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$376$69,60811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in Bayamon

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →